[8-K] Cocrystal Pharma, Inc. Reports Material Event

Rhea-AI Filing Summary

Cocrystal Pharma entered a private placement with four accredited insiders, selling 739,426 units at $1.39 per unit. Each unit includes one common share and a warrant to buy two shares at $1.24 per share for 27 months. The transaction generated $1.03 million in gross proceeds.

The sale was conducted at-the-market under Nasdaq rules and carried no registration rights. The offering relied on Section 4(a)(2) and Rule 506(b) exemptions. If fully exercised, the warrants would be exercisable for 1,478,852 additional shares.

Insights

Capital markets analyst

Small insider-led cash raise with attached warrants; neutral impact.

Cocrystal Pharma raised $1.03 million by selling 739,426 units at $1.39. Each unit adds one issued share and includes a warrant for two more at $1.24 over 27 months, permitting potential future share issuance if exercised.

Because purchasers are insiders and there are no registration rights, near-term resale flows may be limited to exempt transactions. The structure lists standard private placement exemptions under Section 4(a)(2) and Rule 506(b).

If all warrants are exercised for cash, up to 1,478,852 additional shares could be issued, adding cash but increasing share count. Actual impact depends on holder exercise decisions and market conditions.

false 0001412486 0001412486 2025-10-28 2025-10-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 28, 2025

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-38418		35-2528215
(State or other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

19805 N. Creek Parkway Bothell, WA		98011
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 262-7123

(Former name or former address, if changed since last report.): n/a

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		COCP		The Nasdaq Stock Market, LLC (The Nasdaq Capital Market)

Item 1.01 Entry into Material Definitive Agreement.

On October 28, 2025, Cocrystal Pharma, Inc., a Delaware corporation (the “Company” or “Cocrystal”) entered into a Securities Purchase Agreement (“SPA”) with four accredited investors (the “Purchasers”) under which the Purchasers purchased a total of 739,426 units of the Company’s securities. The units were priced at-the-market under the rules of the Nasdaq Stock Market at a purchase price of $1.39 per unit. Each unit consisted of one share of common stock and one warrant to purchase two shares of common stock at an exercise price of $1.24 per share over a 27-month period. The Purchasers did not receive registration rights. The gross proceeds were $1.03 million.

The Purchasers were four insiders of the Company.

The foregoing description of the terms of the SPA and the transactions contemplated thereby does not purport to be complete and is qualified in its entirety by reference to the form of the SPA, a copy of which is incorporated by reference as Exhibit 10.1 to this Current Report on Form 8-K.

Item 3.02 Unregistered Sale of Equity Securities.

The information contained in Item 1.01 is incorporated by reference into this Item 3.02. The sale of units was exempt from registration based upon Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D promulgated thereunder. Each Purchaser is an accredited investor and acquired the units for investment.

Item 7.01 Regulation FD Disclosure.

On October 30, 2025, the Company issued a press release announcing the private placement described above in Item 1.01. A copy of the press release is furnished as Exhibit 99.1.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit		Description
10.1		Form of Securities Purchase Agreement
99.1		Press Release dated October 30, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Cocrystal Pharma, Inc.
Date: October 30, 2025	By:	/s/ James Martin
	Name:	James Martin
	Title:	Co-Chief Executive Officer and Chief Financial Officer

FAQ

What did COCP announce in its 8-K?

A private placement of 739,426 units to four accredited insider investors at $1.39 per unit, raising $1.03 million in gross proceeds.

What securities are included in each COCP unit?

Each unit includes one common share and a warrant to purchase two shares at $1.24 per share for 27 months.

Who purchased the Cocrystal Pharma units?

Four insiders of the Company purchased the units as accredited investors.

Were there registration rights for this COCP private placement?

No. The purchasers did not receive registration rights.

What exemptions were used for the COCP offering?

The sale relied on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.

What are the potential shares from warrant exercises for COCP?

If fully exercised, warrants would be exercisable for 1,478,852 shares at $1.24 per share.

Did COCP issue a press release about the placement?

Yes, a press release was issued on October 30, 2025 describing the transaction.